Results 41 to 50 of about 11,189 (206)

Bromocriptine-associated ototoxicity [PDF]

open access: yes, 1984
Three patients treated with bromocriptine for chronic hepatic encephalopathy showed audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the hearing improved in all three patients when the bromocriptine dosage was reduced, thus
Morgan, MY, Ballantyne, J, Lanthier, PL
core  

Cannabinoid-deficient Benin republic hemp (Cannabis sativa L.) improves semen parameters by reducing prolactin and enhancing anti-oxidant status

open access: yesBMC Complementary and Alternative Medicine, 2019
Background Nigerian Cannabis sativa (hemp) causes male gonadotoxicity by inducing hyperprolactinemia, down-regulation of hypothalamic-pituitary-testicular axis, and oxidative stress.
Abdullateef Isiaka Alagbonsi   +4 more
doaj   +1 more source

Transfer of bromocriptine across the blood-brain barrier in man [PDF]

open access: yes, 1979
The transfer of 14C-bromocriptine across the blood-brain barrier was studied in 10 patients using the double indicator single injection method. The extraction (E) of bromocriptine was 8 % (quartiles: 6 and 14 %).
Hertz, M M, Paulson, O B, Friis, M L
core   +1 more source

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

open access: yesBMC Cardiovascular Disorders, 2021
Background Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from ...
Marianne F. Clausen   +8 more
doaj   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson   +13 more
wiley   +1 more source

The Effects of Bromocriptine on the Estrogen-induced Rat PRL-Secreting Adenomas II. Effects of Bromocriptine on the Distribution of Tubulin and Actin of Adenoma Cells in Vitro [PDF]

open access: yes, 1985
Bromocriptine treatment rapidly lowers the serum prolactin (PRL) level in PRL-secreting adenomas in rats as well as humans. Accompanying immunohistochemical and electron microscopic studies of the adenoma cells treated with bromocriptine for a short ...
丹羽, 潤, 水無頼, 昂
core   +2 more sources

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu   +6 more
wiley   +1 more source

Bromocriptine alters hormone rhythms and lipid metabolism in swine [PDF]

open access: yes, 1989
Hormones, metabolites and activities involved in lipid synthesis were assayed in pigs made leaner by bromocriptine treatment. Market size female swine were allowed free access to food under natural lighting conditions and implanted with bromocriptine ...
Southern, L. L.   +2 more
core   +1 more source

Bromocriptine in type 2 diabetes mellitus [PDF]

open access: yes, 2011
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an ...
Sanjay Kalra, C Shivaprasad
core   +1 more source

Home - About - Disclaimer - Privacy